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IL-2-stimulated NK cells demonstrated synergistic effects 
in the induction of IFNG and GZMB involved in cytotoxic-
ity. The combination of lunasin and cytokines (IL-12 plus 
IL-2) was capable of restoring IFNγ production by NK 
cells from post-transplant lymphoma patients. In addition, 
NK cells stimulated with lunasin plus cytokines displayed 
higher tumoricidal activity than those stimulated with 
cytokines alone using in vitro and in vivo tumor models. 
The underlying mechanism responsible for the effects of 
lunasin on NK cells is likely due to epigenetic modulation 
on target gene loci. Lunasin represents a different class of 
immune modulating agent that may augment the therapeu-
tic responses mediated by cytokine-based immunotherapy.
Keywords Lunasin · NK · Cytokine immunotherapy · 
Lymphoma
Abstract Immunostimulatory cytokines can enhance 
anti-tumor immunity and are part of the therapeutic arma-
mentarium for cancer treatment. We have previously 
reported that post-transplant lymphoma patients have an 
acquired deficiency of signal transducer and activator of 
transcription 4, which results in defective IFNγ production 
during clinical immunotherapy. With the goal of further 
improving cytokine-based immunotherapy, we examined 
the effects of a soybean peptide called lunasin that syn-
ergistically works with cytokines on natural killer (NK) 
cells. Peripheral blood mononuclear cells of healthy donors 
and post-transplant lymphoma patients were stimulated 
with or without lunasin in the presence of IL-12 or IL-2. 
NK activation was evaluated, and its tumoricidal activ-
ity was assessed using in vitro and in vivo tumor models. 
Chromatin immunoprecipitation assay was performed to 
evaluate the histone modification of gene loci that are regu-
lated by lunasin and cytokine. Adding lunasin to IL-12- or 
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Introduction
Cytokine immunotherapy is one of the therapeutic strate-
gies to harness the power of immunosurveillance to eradi-
cate cancer cells. Numerous cytokines have been used in 
clinical trials to enhance anti-tumor immunity [1]. Among 
these cytokines, IFNγ has been recognized as its pivotal 
role in anti-tumor immunity by enhancing tumor immuno-
genicity for antigen presentation [2, 3], inducing apoptosis 
in tumor cells [4], promoting T helper 1 (Th1) differentia-
tion [5, 6] and augmenting cytotoxicity of CD8+ cytotoxic 
T lymphocytes (CTLs) [7]. However, administration of 
recombinant IFNγ had disappointing outcomes in various 
cancer immunotherapy trials possibly due to its toxicity [8]. 
Efforts have focused on induction of endogenous IFNγ by 
natural killer (NK) or T cells following stimulation with 
cytokines IL-2, IL-12, IL-15, IL-18, and IL-21, which have 
been used individually or in different combinations [9–13]. 
The successful production of IFNγ is required for the effi-
cacy of several immunotherapeutic approaches including 
IL-12 immunotherapy [14–16].
IL-12 can be given in biologically active doses to patients 
with lymphoma after high-dose chemotherapy followed 
by autologous peripheral blood stem cell transplantation 
(PBSCT) [17, 18]. However, these heavily treated patients 
have acquired deficiency of signal transducer and activator of 
transcription 4 (STAT4), which contributes to impaired pro-
duction of IFNγ following IL-12 immunotherapy [19, 20]. 
We subsequently defined the mechanism in which acquired 
STAT4 deficiency in T and NK populations is caused by the 
chemotherapeutic regimen [21]. Failure of patient T or NK 
cells to adequately produce IFNγ would likely compromise 
the therapeutic effects during cytokine immunotherapy. The 
goal of this study was to develop an efficacious immune ther-
apy that would enhance anti-tumor activity for chemotherapy-
treated lymphoma patients who acquire immune dysfunctions.
In this study, we have identified a new use for the 
soypeptide lunasin as an immune modulating agent that 
synergistically works with therapeutic cytokines to enhance 
NK-mediated anti-tumor activity. Lunasin is a seed peptide 
containing 43 amino acids [22], known for its chemopre-
ventive properties capable of suppressing tumor growth 
[23]. Our results have demonstrated that lunasin in combi-
nation with IL-12 or IL-2 exerts a robust synergistic effect 
on increasing IFNγ and granzyme B expression by NK 
cells; and this synergism leads to strong NK activation with 
enhanced cytotoxicity. Notably, the combination of luna-
sin and cytokines is capable of rescuing IFNγ production 
by NK cells from heavily treated lymphoma patients who 
are immune compromised. Our results suggest promise for 
lunasin in complementing existing modalities with IL-12 
or IL-2 to improve therapeutic responses of cytokine-based 
cancer immunotherapy.
Materials and methods
Cytokines, antibodies, and lunasin peptides
Recombinant human IL-2 was obtained from Prometheus 
Laboratories (San Diego, CA) and recombinant human 
IL-12 from PeproTech (Rocky Hill, NJ). Fluorochrome-
conjugated monoclonal antibodies to human CD3, CD4, 
CD8, CD14, CD56, FasL (CD178), IFNγ, mouse CD3, 
CD69, NKp46, and human/mouse granzyme B were 
obtained from BD Biosciences (San Jose, CA). Ficoll-
Paque™ PLUS was purchased from GE Healthcare Bio-
Sciences (Piscataway, NJ). The lunasin peptide with 43 
amino acids was chemically synthesized with 97 % purity 
by LifeTein (South Plainfield, NJ), which include the fol-
lowing sequences: SKWQHQQDSCRKQLQGVNLTP-
CEKHIMEKIQGRGDDDDDDDDD. A truncated peptide 
(32 amino acids) lacking the RGD motif and the poly-D 
tail was synthesized by LifeTein. A negative control pep-
tide with scrambled sequences (RKMELQEGI HLKKG-
DQNTQSQSCQPKC IQVWH) that maintains the same 
molecular weight to the truncated peptide was synthe-
sized. An additional negative control peptide containing an 
epitope from the influenza matrix protein (M158–66) which 
binds to human MHC class I molecules was also synthe-
sized. All the peptides were dissolved in sterilized water at 
stock concentration of 5 mM.
Human blood samples and primary cell cultures
Collection of blood was approved by the Institutional 
Review Board at Indiana University Medical Center, and 
written informed consent was obtained from each study 
subject. Blood samples were obtained from patients with 
lymphoma after treatment with high-dose chemotherapy 
and PBSCT. Healthy human blood samples were pro-
cured from the Indiana Blood Center (Indianapolis, IN). 
Peripheral blood mononuclear cells (PBMCs) were iso-
lated using Ficoll-Paque™ PLUS, and aliquots of PBMCs 
were cryopreserved in liquid nitrogen. Human NK cells 
were isolated from normal control PBMCs using positive 
or negative selection kits (Miltenyi Biotech, Auburn, CA). 
Human B lymphoma cell line Raji cell line was obtained 
from American Type Culture Collection (ATCC, Manas-
sas, VA, USA).
Evaluation of IFNγ production
IFNγ production at the single-cell levels was evaluated 
using intracellular cytokine staining from PBMCs follow-
ing stimulation as indicated [24]. Secreted IFNγ protein 
collected from the supernatant or mouse serum was meas-
ured using ELISA [19, 20].
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Analysis of gene expression
Purified human NK cells were stimulated as indicated. One 
day following stimulation, the cell pellets were subjected 
to analysis of gene expression using real-time qPCR with 
Taqman assay primers for IFNG, CSF2, GZMB, TGFB1, 
and TGFBR2.
The half-maximal effective concentration (EC50) of lunasin
The EC50 of lunasin was calculated from the dose–
response curve in IFNγ production using Origin Program 
(OriginLab, Northampton, MA). The EC50 is presented as 
mean ± SD averaged from four different normal controls.
In vitro cytotoxicity assays
Purified human NK cells stimulated as indicated for 1 day 
were washed and co-cultured with target cells (Raji) at 
the ratio of 10:1 for 4 h at 37 °C in a 5 % CO2 incuba-
tor. NK-mediated lysis was analyzed using the CytoTox 96 
Non-Radioactive Cytotoxicity Assay Kit (Promega, Madi-
son, WI). For some assays, NK cells were incubated with 
anti-FasL-blocking antibody (NOK-1 clone, BioLegend) or 
the isotype control (IgG1) at 10 μg/ml for 2 h [25] followed 
by co-culturing with Fas-expressing target cells (Raji).
Adoptive transfer of human NK cells in xenograft model 
in vivo
NOD/SCID/gcnull (NSG) mice (The Jackson Laboratory, 
Bar Harbor, Maine) at 2 months old were injected subcu-
taneously on day 1 with 0.5 × 106 Raji cells in 0.1 ml PBS 
mixed with 0.1 ml Matrigel (BD Biosciences, San Jose, 
CA). Human NK cells isolated from healthy control donors 
were stimulated as indicated for 1 day. On day 2, these pre-
treated NK cells were washed and injected into the tumor 
site (2.5 × 106/mouse). Tumor growth was monitored, 
and the volumes were measured using standard manual 
calipers.
NK activation in mice following short-term and long-term 
treatment
BALB/c mice received short-term (daily single IP injec-
tion for 3 consecutive days) or long-term (daily single IP 
injection for 5 consecutive days per week for a total of 
8 weeks) treatment with PBS (−), IL-2 (1 × 105 U/mouse) 
without (−) or with (+) lunasin (0.4 mg/kg body weight), 
or lunasin alone. Blood samples were collected by cardiac 
puncture, and serum levels of IFNγ were determined using 
ELISA. NK activation was analyzed from spleens in these 
mice using staining antibodies for surface activation marker 
CD69 and intracellular granzyme B. IFNγ production by 
NK cells was evaluated using intracellular staining from 
splenocytes that were incubated with GolgiPlug (Brefeldin 
A) for 4 h at 37 °C in a 5 % CO2 incubator followed by 
flow cytometry analysis.
Chromatin immunoprecipitation (ChIP)
The ChIP experiment was performed using isolated human 
NK cells treated 1 day as indicated following the estab-
lished protocol [26, 27]. Antibodies against acetyl-histone 
H3 (AcH3), histone H3 trimethyl Lys9 (H3K9me3), and 
non-immune rabbit serum were obtained from Millipore 
(Billerica, MA).
Analysis of STAT4 activation by Western blot
Purified human NK cells were stimulated for 22 h. Western 
blot analysis was performed from total protein extracts of 
cultured NK cells to measure the activation of STAT4 using 
an anti-phospho-STAT4 (Y693) antibody (Cell Signaling 
Technology, Danvers, MA). The same blot was reprobed 
with an anti-STAT4 monoclonal antibody (BD Biosciences, 
San Jose, CA) for the total amount of STAT4.
Statistical analysis
SAS/STAT (SAS Institute Inc., Cary, NC) was used to ana-
lyze the data. A mixed model was developed for analyz-
ing the data with within-subject treatments, and the pair-
wise comparisons among the treatments were performed 
to determine the P values. Statistical significance between 
groups of mice was determined using an independent sam-
ple Student’s t test.
Results
Lunasin stimulates human NK cells to produce IFNγ
To determine whether lunasin can induce cellular IFNγ 
production, PBMCs from healthy donors were stimulated 
with or without lunasin in the presence or absence of IL-12 
or IL-2. Because IL-12 and IL-2 are known to induce the 
production of IFNγ by NK cells [1], these two cytokines 
were included in the stimulation for comparison. Follow-
ing 1 day of stimulation, distinct cell populations that 
responded to stimulation were evaluated using intracel-
lular staining for IFNγ. We found that CD4+ and CD8+ 
T populations remained negative with all stimuli (data not 
shown), while NK cells gated on CD3− CD56+ popula-
tions (Fig. 1a) had increased IFNγ positive cells follow-
ing stimulation with lunasin and IL-12 or IL-2 compared 
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with cytokine alone (Fig. 1b, c). CD56 bright subsets of 
NK cells are major IFNγ producers with regulatory func-
tions, while CD56 dim populations exert cytolytic activity 
[28, 29]. We also analyzed intracellular IFNγ production 
by CD56 bright and dim populations (Fig. 1d), and results 
showed that adding lunasin to IL-12- or IL-2-cultured NK 
cells stimulated IFNγ production by both CD56 bright and 
dim populations (Fig. 1e). The effect of lunasin on NK cells 
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was further confirmed by stimulation of purified human NK 
cells using either positive selection (purity ranging from 
80 to 92 %) or negative selection (purity 97 %). Results 
showed that exposure of lunasin in combination with IL-12 
or IL-2 markedly increased the levels of IFNγ secreted by 
purified NK cells irrespective of the method of purification 
(Fig. 1f). The mRNA expression of IFNG from the cell pel-
lets of the same cultures correlated with the ELISA results 
(Fig. 1g). Consistent with intracellular staining, purified 
CD4+ or CD8+ T cells produced undetectable levels 
of IFNγ under the same stimulation conditions (data not 
shown). Thus, exposure of NK cells to lunasin amplifies the 
responsiveness of these cells to IL-12 or IL-2 as measured 
by IFNγ production.
Lunasin regulates gene expression by NK cells
Because of robust synergistic effects of lunasin with IL-12 
or IL-2 on inducing IFNG expression, we next evaluated 
whether lunasin was able to modulate other target genes 
that are regulated by IL-12 or IL-2. Results of qPCR from 
samples in Fig. 1g showed that adding lunasin to IL-12 or 
IL-2 significantly increased expression of GZMB (gran-
zyme B) and CSF2 (granulocyte–macrophage colony-
stimulating factor or GM-CSF) as compared to treatment 
with cytokine alone (Fig. 1h). Cytokine IL-12 or IL-2 
stimulation is known to downregulate TGFB1 and TGFBR2 
expression by NK cells [30], and adding lunasin to 
cytokine-treated NK cultures resulted in further reduction 
of TGFB1 and TGFBR2 expression as compared to treat-
ment with cytokines alone (Fig. 1i). Thus, it appeared that 
lunasin exerted synergistic effects imposed by the selected 
cytokine IL-12 or IL-2 on modulating expression of target 
genes in NK cells.
Dose-dependent effects of lunasin in combination 
with cytokines
To define the dose response of lunasin in combination 
with cytokines, we determined the EC50 based on the 
IFNγ production by IL-12-cultured human NK cells. At 
IL-12 concentration of 10 ng/ml, the EC50 for lunasin was 
5.64 ± 2.23 μM (n = 4) (Fig. 2a). To determine whether 
lunasin could amplify the synergistic induction by cytokine 
cocktails with IL-2 and IL-12, human NK cells were cul-
tured in both cytokines without or with lunasin. Based 
on the EC50 of lunasin, we chose its concentrations of 5, 
20, and 80 μM. We found that lunasin also synergisti-
cally worked with cytokine cocktails on IFNγ production 
(Fig. 2b).
Rescuing IFNγ production by NK cells from lymphoma 
patients post-transplant
As reported previously, STAT4 deficiency was observed 
in lymphoma patients after PBSCT [21]. Stimulation of 
patient PBMCs with both IL-12 and IL-2 resulted in pro-
duction of IFNγ by NK populations using intracellular 
staining (Fig. 3a), albeit at a much lower percentage as 
compared to cells from normal controls (Fig. 3b). However, 
adding lunasin to the stimulation further increased the per-
centage of patient NK cells that produced IFNγ, which was 
similar to the level from normal controls stimulated with 
both cytokines (P = 0.446) (Fig. 3b). Thus, incorporat-
ing lunasin into cytokine-based treatment may rescue the 
production of IFNγ by NK cells from heavily treated lym-
phoma patients with acquired STAT4 deficiency.
Lunasin augments cytotoxicity by cytokine-activated NK 
cells
NK cells cultured in medium exhibited poor cytolytic 
activity against Raji lymphoma cells that are resistant to 
NK-mediated killing (Fig. 4a). Cytokine treatment led to 
NK activation, which enhanced the cytotoxicity against 
Fig. 1  Lunasin stimulates human peripheral NK cells. Peripheral 
blood mononuclear cells (PBMCs) of normal controls were stimu-
lated with medium only (−), lunasin at 20 μM (lu), cytokine IL-12 
at 10 ng/ml or IL-2 at 100 U/ml, and cytokine plus lunasin for 24 h. 
The lunasin peptide was chemically synthesized by LifeTein (South 
Plainfield, NJ). The production of IFNγ at single-cell levels was ana-
lyzed using intracellular cytokine staining (a–e). At the last 6 h of 
stimulation, golgistop (monensin) was added to block the secretion of 
IFNγ. Stimulated PBMCs were surface stained with FITC-conjugated 
CD3 and APC-conjugated CD56 monoclonal antibodies, washed, 
fixed, and permeabilized. After washing, cells were incubated with 
PE-conjugated anti-IFNγ monoclonal antibody. Expression of IFNγ 
was evaluated using flow cytometry on 5,000 events of gated CD3 
negative and CD56 positive NK cell populations (a). A representa-
tive dot plot from one donor shows the percentage of IFNγ producing 
NK populations following various treatments (b), and the averaged 
percentage of IFNγ producing NK populations are presented as 
mean ± SD from 5 different normal donors (c). IFNγ producing NK 
cells are further segregated into CD56 bright and CD56 dim popu-
lations (d), and the percentage of IFNγ producing CD56 bright or 
CD56 dim populations is averaged from the same 5 donors as in c 
and presented as mean ± SD (e). f The secretion of IFNγ by purified 
NK cells following stimulation was analyzed using ELISA. Freshly 
isolated human NK cells from PBMCs of normal controls using posi-
tive selection with CD56 magnetic beads (Miltenyi Biotec, Auburn, 
CA) were stimulated as in b. Following 1 day of stimulation, cell-free 
supernatants were evaluated for IFNγ production, and data are pre-
sented as mean ± SD averaged from 5 different controls. g–i Effects 
of lunasin on gene expression by human NK cells. The cell pellets 
collected from f were resuspended in Trizol Reagents for total RNA 
extraction. The first-strand cDNA was synthesized followed by real-
time qPCR using Taqman assay with primers for g IFNγ (IFNG), h 
granzyme B (GZMB) and granulocyte–macrophage colony-stimu-
lating factor (GM-CSF or CSF2), and i TGFβ (TGFB1) and TGFβ 
receptor (TGFBR2) in ABI 7300 (Applied Biosystems by Life Tech-
nologies, Carlsbad, CA). Data are presented as mean ± SD averaged 
from 5 different controls. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001
◂
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Raji cells (Fig. 4a). Moreover, lunasin further augmented 
the natural cytotoxicity of NK cells that were negatively 
selected (97 % purity) and stimulated with suboptimum 
concentrations of cytokines against Raji cells (Fig. 4a).
Granzyme B is constitutively expressed by human periph-
ery NK cells, and its level is associated with the lytic activity. 
IL-2 appeared to induce a higher GZMB by total NK cells as 
compared to IL-12 (Fig. 1h, upper panel). We next analyzed 
the effects of suboptimum IL-2 with or without lunasin on 
the expression of granzyme B using intracellular staining. 
In concert with the gene expression result, lunasin increased 
the protein levels of granzyme B in total NK cells cultured 
in IL-2 (MFI 140 ± 99 for IL-2-treated vs. 163 ± 104 for 
IL-2+ lunasin-treated NK; mean ± SD averaged from 3 
controls). We also found that both CD56 bright and dim pop-
ulations had a higher granzyme B when lunasin was included 
in the culture as compared to IL-2 only (Fig. 4b).
To investigate whether lunasin could affect the FasL-
induced apoptosis by IL-2-cultured NK cells, we first 
evaluated the surface expression of FasL following 1 day 
Fig. 2  Dose-dependent effects of lunasin in combination with 
cytokines. Freshly isolated human NK cells from PBMCs of normal 
controls (described in Fig. 1f) were stimulated as indicated, and the 
production of IFNγ in the supernatants was determined using ELISA 
following one day of stimulation. a The half-maximal effective con-
centration (EC50) of lunasin was calculated from the dose–response 
curve in IFNγ production by NK cultured with IL-12 at 10 ng/ml 
using Origin Program (OriginLab, Northampton, MA). One rep-
resentative curve based on the dose response in IFNγ production is 
shown. The EC50 is presented as mean ± SD averaged from 4 differ-
ent normal controls. b Isolated NK cells as described in a were stimu-
lated with both cytokines (IL-2 at 10 U/ml and IL-12 at 1 ng/ml) in 
the combination with lunasin at different concentrations ranging from 
5, 20, and 80 μM. One day following stimulation, the production 
of IFNγ in the supernatants was determined using ELISA. Data are 
presented as mean ± SD averaged from 3 different normal controls. 
*P ≤ 0.05 Fig. 3  Rescuing IFNγ production by NK cells from lymphoma 
patients post-transplant. PBMCs of normal controls and post-trans-
plant lymphoma patients were stimulated with medium only (−), 
IL-12 (10 ng/ml) and IL-2 (100 U/ml), IL-12 and IL-2 plus lunasin 
(lu, 20 μM), or lunasin alone for 1 day. The production of IFNγ at 
single-cell levels was analyzed using intracellular cytokine stain-
ing as described in Fig. 1a, and a representative dot plot from one 
control and patient is shown in a. The percentage of IFNγ positive 
NK populations (CD3 negative and CD56 positive) are presented as 
mean ± SD averaged from 6 normal controls and 5 patients (1 patient 
at 6–12 month and 4 patients at 3–6 months post-transplant) (b). 
*P ≤ 0.05
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stimulation. Flow cytometry analysis showed minimum 
effects of lunasin on surface expression of FasL in NK cells 
cultured in suboptimum IL-2 (3 ± 1.2 % of FasL + NK 
in IL-2-treated vs. 2.7 ± 0.8 % in IL-2+ lunasin-treated, 
n = 2). In addition, cultured NK cells treated with FasL-
blocking antibody or the isotype control had similar killing 
activity against Fas-expressing Raji target cells (Fig. 4c), 
suggesting that lunasin had no effect on FasL-mediated 
killing by NK cells activated with suboptimum IL-2.
Cellular therapy using NK cells activated in vitro has 
been tested clinically against several tumors [31–33]. In a 
Raji lymphoma xenograft model, tumor growth increased 
over time in the control mice without transferred human NK 
cells (Fig. 4d). While tumor growth was attenuated at day 
27 in mice receiving cytokine-activated NK cells, the group 
receiving NK cells activated with lunasin and cytokine had 
lowest tumor size when compared with the control group 
without transferred human NK cells (Fig. 4d).
In vivo effect of lunasin on serum IFNγ secretion
To assess whether lunasin could enhance IFNγ production 
in vivo, BALB/c mice were given single IP injection with 
IL-2 in the presence and absence of lunasin as indicated. 
Eighteen hours following the treatment, we were unable to 
detect serum IFNγ levels from mice receiving PBS, IL-2, 
or lunasin. In contrast, the combination of IL-2 and lunasin 
resulted in the secretion of IFNγ in the serum using lunasin 
at the dose at 0.4 mg/kg body weight (Fig. 5a).
NK activation in vivo following short-term treatment
The effects of lunasin in vivo on NK activation were 
examined. Given the toxicity-related death caused by 
cytokine storm with high levels of IFNγ [34], we thus 
chose the regimen of IL-2 at suboptimal dose in order 
to keep animal alive for analysis. We analyzed NK cells 
gated on CD3−NKp46+ populations (Fig. 5b) from 
spleens of mice receiving short-term treatment (daily sin-
gle IP injection for 3 days). The combination of lunasin 
and IL-2 resulted in significant increase in the percent-
age of CD69+ or granzyme B + NK cells as compared to 
those treated with PBS (Fig. 5C, upper and middle panels). 
Intracellular staining identified NK cells to be responsible 
for IFNγ production in mice treated with both lunasin and 
IL-2 (Fig. 5c, lower panel). While IL-2 at suboptimal dose 
had undetectable effects in this short-term treatment, add-
ing lunasin to IL-2 was able to induce NK activation.
NK activation in vivo following long-term treatment
Following long-term treatment (daily single IP injection 
for 5 days per week with a total of 8 weeks), these mice 
exhibited similar percentage of NK cells (CD3−NKp46+) 
and spleen cellularity (data not shown). Long-term treat-
ment with IL-2 in this setting resulted in NK activation 
(evidenced by increased expression of CD69, granzyme 
B, and IFNγ; Fig. 5d) as well as increased levels of serum 
IFNγ (Fig. 5e). In the presence of lunasin, however, the in 
vivo effects of IL-2 on NK activation and serum IFNγ pro-
duction were compromised (Fig. 5d, e).
Mechanisms of synergistic effects mediated by lunasin
Lunasin peptide contains a RGD motif that is involved in 
the binding of integrins that are expressed on various cell 
types including NK cells [35]. To directly study the func-
tion of RGD motif in lunasin, a truncated peptide lacking 
the RGD motif and the poly-D tail, a negative control pep-
tide containing scrambled amino acids, and an influenza-
derived peptide that binds to MHC class I molecules, were 
chemically synthesized. This truncated peptide induced 
similar levels of IFNγ in NK cells compared with that 
using the full-length lunasin (Fig. 6a), suggesting the last 
11 amino acids are not required for lunasin’s immune 
modulatory function in NK cells although they are critical 
for inducing apoptosis in transformed cancer cells [36]. In 
addition, the scrambled negative control peptide as well as 
influenza-derived peptide did not induce detectable levels 
of IFNγ (Fig. 6a, and data not shown), which ruled out the 
non-specific effects at the concentrations used (20 μM).
It has been shown that lunasin is capable of inhibiting 
the acetylation of histone H3 by p300/CBP-associated fac-
tor (PCAF), a histone acetylase enzyme [23]. Epigenetic 
regulation by chromatin modification is known to alter 
gene expression [37]. The effects of lunasin on epigenetic 
regulation of NK cells were examined. Consistent with 
gene expression profiles of TGFB1 (Fig. 1i, upper panel), 
the level of acetylated histone H3 (AcH3) was negatively 
associated with TGFB1 locus, and less DNA was pulled 
down by the anti-AcH3 antibody in NK cells treated with 
lunasin and IL-12 as compared to that with IL-12 alone 
(Fig. 6b, lower panel). Conversely, the level of AcH3 was 
positively associated with IFNG locus to a greater degree 
in NK cells treated with lunasin plus IL-12 than that treated 
with cytokine alone (Fig. 6b, upper panel). Results suggest 
the ability of lunasin for modulating the levels of AcH3 
bound to the target genes, resulting in gene regulation.
Histone mark with tri-methylated histone H3 at lysine 
9 (H3K9me3) is associated with transcriptional repres-
sion [38]. We next tested whether changes in the repres-
sive epigenetic marker H3K9me3 were also associated 
with IL-12-mediated gene regulation in NK cells. Results 
in Fig. 6c showed a very limited binding of H3K9me3 in 
the gene loci including TGFB1 and IFNG, suggesting 
that H3K9me3 was not involved in IL-12-mediated gene 
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regulation in NK cells, and adding lunasin had no effect on 
levels of H3K9me3 bound to these loci.
STAT4 activation in lunasin-cultured NK cells
STAT4 is required for IL-12-induced IFNγ production by 
T and NK cells [20, 39, 40], and its activation is involved 
in H3 hyperacetylation at Ifng locus [41]. In this study, we 
observed activation of STAT4 in human NK cells follow-
ing IL-2 stimulation, albeit stronger phospho-STAT4 was 
induced by IL-12 (Fig. 6d). The levels of pSTAT4 were 
higher in the cytokine-cultured NK cells containing lunasin 
(Fig. 6d), suggesting that adding lunasin to cytokine-cul-
tured NK cells enhanced STAT4 activation, which may also 
contribute to induction of IFNG by NK cells.
Discussion
Lunasin was first described for its chemopreventive proper-
ties that have been demonstrated in cell cultures and mice 
models [23]. In this study, we have found that lunasin exerts 
synergistic effects with cytokine IL-12 or IL-2 on modu-
lating expression of a number of genes in NK cells. This 
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synergism results in strong NK activation with enhanced 
cytotoxicity, which is associated with higher levels of IFNγ 
and granzyme B expressed by both CD56 bright and dim 
populations. Adding lunasin to cytokine cocktails with both 
IL-12 and IL-2 was capable of rescuing the production of 
IFNγ by NK cells from post-transplant lymphoma patients 
(Fig. 3), suggesting its potential application as an alterna-
tive strategy to improve the clinical outcomes by circum-
venting chemotherapy-induced immune dysfunction. Taken 
together, our results demonstrate that the combination of 
lunasin and selected cytokine (designated as lunakine) is 
superior to cytokine alone for harnessing NK-mediated 
anti-tumor functions.
In addition to cytokine stimulation, NK cells can be acti-
vated by engagement of co-stimulatory molecules through 
direct contact with other innate immune cells [42]. Interac-
tion between activated γδT and NK cells increases the cyto-
toxicity of NK cells via the CD137 engagement [43]. Thus, 
there is a possibility that γδT or other innate immune cells 
remaining in the NK cultures following negative selec-
tion (97 % purity) may respond to treatment, which in turn 
activate NK cytotoxicity. Future studies will need to define 
cell types that can respond to lunasin-based treatment, as 
well as target genes that are regulated by such treatment. 
Our results suggest that enhanced cytotoxicity of NK cells 
following combination treatment with lunasin and cytokine 
is at least in part due to up-regulation of granzyme B that 
involves in the granule exocytosis pathway.
Using the Raji B lymphoma xenograft model, we 
showed that lunakine-treated NK cells could be used in 
cellular therapy following adoptive transfer (Fig. 4d). 
However, lunasin did not increase the number of NK cells 
cultured in cytokines (data not shown), suggesting its lim-
ited effect on survival or expansion of NK cells in cellular 
therapy. Nonetheless, we verified lunasin’s in vivo effect 
on IFNγ production and NK activation from mice follow-
ing short-term treatment with IL-2 and lunasin (Fig. 5a–c). 
The suppressive effect following the long-term treatment 
(Fig. 5d, e) was not likely caused by the reduced number of 
NK cells systemically as these mice exhibited similar per-
centage of NK cells and total spleen cellularity (data not 
shown). Although the 8-week treatment used in our study 
is not a current practice, this result raises precautions in the 
future use of lunasin peptide, in which immune suppression 
is induced following immune activation in order to maintain 
homeostasis and avoid the unwanted immune responses. It 
will be imperative to optimize the doses of each agent and 
duration of treatment and to evaluate the bioavailability, 
biodistribution, and pharmacokinetic (PK) profile for luna-
sin in order to fully realize its clinical potential.
The synergistic effects of lunasin with selected cytokine 
such as IL-12 are in part due to reducing the levels of 
acetyl-H3 (Fig. 6b, lower panel), which further suppresses 
the expression of TGFB1 (Fig. 1i, upper panel). However, 
acetyl-H3 is associated with IFNG locus to a greater degree 
in NK cells treated with IL-12 plus lunasin than those 
treated with IL-12 only (Fig. 6b, upper panel). If the role 
of lunasin is solely dependent on inhibiting acetylation of 
histone, how can lunasin coordinately up- and down-reg-
ulate expression of different gene loci? One possibility is 
that lunasin can bind not only deacetylated but also acety-
lated histone proteins depending upon the preconditioned 
Fig. 4  Effects of lunasin on NK cell-mediated cytotoxicity against 
human B lymphoma Raji cell line. a NK-mediated cytotoxicity in 
vitro. Freshly isolated human NK cells from PBMCs of normal con-
trols using negative selection (Miltenyi Biotec) were stimulated with 
medium only (−), single or both cytokines (IL-12 and IL-2) with-
out (−) or with (+) lunasin (20 μM), or lunasin alone for 1 day. 
Cytokines were used at suboptimum concentrations of 1 ng/ml for 
IL-12 and 10 U/ml for IL-2. The in vitro cytotoxicity was performed 
using lactate dehydrogenase (LDH)-releasing assay with the CytoTox 
96 Non-Radioactive Cytotoxicity Assay Kit (Promega, Madison, WI). 
The effectors were co-cultured with target cells at ratio of 10:1 for 
4 h at 37 °C in a 5 % CO2 incubator. The percentage of cytotoxic-
ity was calculated according to the manufacturer’s instructions. Each 
symbol represents an individual donor, and the percentage of cytotox-
icity from each donor (n = 5, C70, C05, C83, C37, and C40) follow-
ing various treatments is depicted in the upper panel of a. The aver-
aged percentage of cytotoxicity from 3 to 4 donors at each treatment 
is presented as mean ± SD in the lower panel of a. A mixed model 
including 6 levels of treatments was developed to analyze the data 
with within-subject treatments, and the pairwise comparisons among 
the treatments were performed to determine the P values. *P ≤ 0.05; 
**P ≤ 0.01. b Intracellular granzyme B staining from activated NK 
cells. Purified NK cells as in a were stimulated with suboptimum 
concentration of IL-2 (10 U/ml) alone or with lunasin (20 μM) for 
1 day followed by intracellular staining for granzyme B. The level of 
granzyme B expression was analyzed from CD56 bright and CD56 
dim NK populations, and the geometric mean fluorescent intensity 
(MFI) was obtained using flow cytometry. The MFI of bright and dim 
populations treated with IL-2+ lunasin was compared to IL-2, and 
the percentage of increase in granzyme B expression is presented as 
Mean ± SD averaged from 3 controls (b). c FasL-mediated killing 
by activated NK cells. Purified NK cells were stimulated as in b for 
1 day followed by incubation with blocking antibody against FasL 
(filled bar) or IgG isotype control (open bar) for 2 h. FasL-mediated 
killing by activated NK cells was determined using the in vitro cyto-
toxicity assay as in a. The percentage of cytotoxicity against Raji 
cells is presented as mean ± SD averaged from 2 controls. d NK-
mediated cytotoxicity in a human Raji lymphoma xenograft model. 
NOD/SCID/gcnull (NSG) mice at 2 months old were injected subcu-
taneously on day 1 with 0.5 × 106 Raji cells in 0.1 ml PBS mixed 
with 0.1 ml Matrigel (BD Biosciences, San Jose, CA). NK cells were 
isolated from the leucopack of donors and treated with IL-2 (10 U/
ml) or IL-2+ lunasin (lu, 20 uM) for 1 day. On day 2, these treated 
NK cells were washed and injected into the tumor site (2.5 × 106 NK 
cells/mouse). Tumor growth was monitored, and the volumes were 
measured using standard manual calipers. Tumor volume (mm3) is 
presented as mean ± SD from 9 mice in the control group of Raji 
(no NK), and from 7 mice in the groups of Raji + NK (IL-2), and 
Raji + NK (IL-2+ lunasin). A mixed model with repeated measure 
to the data was developed using PROC MIXED in SAS program fol-
lowed by pairwise comparison test of the mean differences among 
treatments by different days. *P ≤ 0.05; **P ≤ 0.01; relative to the 
control group of Raji (no NK)
◂
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Fig. 5  In vivo effects of lunasin. a Lunasin enhances the secretion 
of IFNγ in the serum. BALB/c mice received single intraperitoneal 
(IP) injection with PBS (−), IL-2 (1 × 105 U/mouse) without (−) or 
with (+) lunasin (0.4 mg/kg body weight), or lunasin alone as indi-
cated. Mice were killed 18 h following injection, and blood samples 
were collected by cardiac puncture. The serum levels of IFNγ were 
analyzed using ELISA. Data are presented as mean ± SD from 3 
mice per group. ND, not detectable. b, c NK activation in vivo fol-
lowing short-term treatment. BALB/c mice received single daily IP 
injection for 3 consecutive days as indicated. The following day mice 
were killed, and spleens were collected for analysis of NK activation 
using flow cytometry. NK cells gated on CD3− NKp46+ populations 
(b) were analyzed for surface expression of activation marker CD69 
(c, upper panel) and intracellular staining for granzyme B (c, middle 
panel). The production of IFNγ was analyzed from splenocytes that 
were incubated with GolgiPlug (Brefeldin A) for 4 h in vitro, and NK 
populations gated in b were analyzed for intracellular IFNγ expres-
sion using flow cytometry (c, bottom panel). Data are presented as 
mean ± SD averaged from 5 mice per group. d–e NK activation in 
vivo following long-term treatment. BALB/c mice received sin-
gle daily IP injection for 5 consecutive days per week for a total of 
8 weeks as indicated. Three days after the last injection, mice were 
killed, and spleens were collected for analysis of NK activation (d) 
using the same parameters as described in c. Blood samples were 
collected for analysis of serum IFNγ using ELISA (e). Data are pre-
sented as mean ± SD averaged from 5 mice per group. *P ≤ 0.05; 
**P ≤ 0.01; ***P ≤ 0.001
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chromatin structure created by the selected cytokine such 
as IL-12. To identify histones that can physically interact 
with lunasin, we screened over 384 unique histone modifi-
cations using histone peptide assays (Active Motif, Carls-
bad, CA). Indeed, lunasin is capable of binding to deacet-
ylated H3 as well as H3 modifications that are associated 
with both gene activation and repression (data not shown). 
It has been shown that the level of acetyl-H3 is augmented 
following stimulation with IL-12, which contributes to 
induction of IFNG by NK cells [44]. We thus speculate 
that lunasin binds to the histone mark (acetyl-H3) created 
by initial cytokine exposure such as IL-12 [44], and this 
binding protects the target gene loci from changing its epi-
genetic state, and results in maintaining and stabilizing a 
nucleosome structure favorable for promoting transcription 
of target genes.
The molecular mechanisms mediated by lunasin require 
further investigation. Nonetheless, our results suggest 
that lunasin likely acts as an epigenetic modulator, which 
synergistically works with cytokines on regulating expres-
sion of susceptible genes in NK cells. Our discovery for 
the novel property of lunasin represents a different class of 
immune modulating agent that may augment the therapeu-
tic responses by cytokine-based immunotherapy.
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Fig. 6  Mechanisms of synergistic effects mediated by lunasin. a 
The RGD motif and poly-D tails are not required for the synergistic 
effects of lunasin on IFNγ production by NK cells. Freshly isolated 
human NK cells (described in Fig. 1f) were stimulated with medium 
only (−), IL-12 (10 ng/ml) without (−) or with (+) the full-length 
lunasin (Lu), mutant peptide (Mt) lacking the RGD motif and poly-D 
tail, or negative control (NC) peptide with scrambled amino acids as 
well as peptides only as indicated. The concentrations of the peptides 
used were 20 μM. One day following stimulation, the production of 
IFNγ in the supernatants was determined using ELISA. Data are pre-
sented as mean ± SD averaged from 2 different normal controls. b, 
c Chromatin remodeling at the loci of target genes. Freshly isolated 
human NK cells (described in Fig. 1f) were stimulated with medium 
only (−), IL-12 (10 ng/ml) without (−) or with (+) lunasin (20 μM), 
or lunasin alone. Following 1 day of stimulation, cells were subjected 
to the ChIP assay. Chromatin DNA fragments were immunoprecipi-
tated with antibodies against acetyl-histone H3 (AcH3) (b) and his-
tone H3 trimethyl Lys9 (H3K9me3) (c) along with non-immune rab-
bit serum (filled bars) (Millipore, Billerica, MA), individually. The 
relative degree of histone modification of IFNG and TGFB1 loci 
was compared by qPCR using ChIP qPCR Primer Assay for human 
IFNG (+1 kb) and TGFB1 (+1 kb), respectively (SABioscience 
Qiagen, Valencia, CA). For calculation of ChIP results, the amount 
of immunoprecipitated DNA is normalized to the input chromatin in 
each reaction as a percentage of input (% input). Data are shown as 
mean percentage of input ± SD averaged from 3 controls. *P ≤ 0.05. 
d STAT4 activation in lunasin-cultured NK cells. Freshly isolated 
human NK cells from PBMCs of normal controls (described in 
Fig. 1f) were stimulated with single cytokine IL-2 (10 U/ml) or IL-12 
(1 ng/ml), or both cytokines in the absence (−) and presence (+) of 
lunasin (20 μM) as well as medium and lunasin only. Activation of 
STAT4 was determined using Western blot of total protein extracts 
from cultured NK cells following 22 h of stimulation. Ratios of phos-
pho-STAT4 to total STAT4 (pSTAT4/total STAT4) were determined 
from the arbitrary units of densitometry using the NIH ImageJ pro-
gram as indicated. An anti-β-actin monoclonal (SC-47778) antibody 
(Santa Cruz Biotechnology, Santa Cruz, CA) was used for the load-
ing control. Results shown are representative from 2 different normal 
controls with similar profiles
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